Case Series

Disseminated talaromycosis: an AIDS defining fungal infection

Bijayanti Devi1, Sana S.1*, Bharath Meka1, Bhuvanesh Raj2

1Department of Dermatology, Venereology and Leprology, 2Department of Microbiology, Regional Institute of Medical Sciences, Imphal, Manipur, India

Received: 05 June 2020
Accepted: 29 July 2020

*Correspondence:
Dr. Sana S.,
E-mail: sanashems@gmail.com

ABSTRACT

Talaromycosis is a systemic mycosis caused by Talaromyces marneffei. It mostly occurs as an opportunistic infection in patients with human immunodeficiency virus (HIV). In India, its endemic in Manipur. We report 3 cases of disseminated talaromycosis with skin eruptions in HIV sero-positive patients from Manipur.

Keywords: Talaromycosis, Talaromyces marneffei, AIDS, cutaneous penicilliosis

INTRODUCTION

Talaromycosis (aka Penicilliosis) is a systemic mycosis caused by Talaromyces marneffei (earlier - Penicillium marneffei), predominantly in immunocompromised patients. There is a strong association with AIDS. It ranks third in opportunistic infections behind tuberculosis and cryptococcosis in patients with acquired immunodeficiency syndrome (AIDS).1-3 The disease is endemic in several regions of Southeast Asia including Thailand, Malaysia, South China, Indonesia and Vietnam. In India, it is endemic in Manipur state in Northeast India as evidenced by reports of numerous autochthonous cases from this state.4,5 A few imported cases of T.marneffei infection have been reported from non-endemic areas of India.4,9 A lot is still unknown about the natural reservoir and route of transmission of T.marneffei. Human and bamboo rats are the only known animal hosts of T. marneffei.

CASE REPORT

Case 1

A 44 year old male, farmer from Manipur presented with multiple asymptomatic papules on face and trunk since 1 week with history of fever, cough, loose stools, loss of appetite, weight loss for past 2 months. The patient was known to be HIV seropositive and was on antiretroviral therapy (ART) for past 1 month. Skin lesions started 15 days after initiation of ART drugs (tenofovir, efavirenz, lamivudine (TEL)). Lesions started on forehead and progressed to involve whole face, trunk and bilateral upper extremities. There were no oro-gential lesions. On cutaneous examination multiple skin coloured flat topped, umbilicated and dome shaped papules, plaques and few nodules with umbilication and central hemorrhagic crusts distributed over face, neck, bilateral pinna, trunk, bilateral upper limbs noted (Figure 1).

Laboratory investigations revealed Hb 8 gm%, plt 90,000/mm3, ESR- 110 mm/ 1st hr. HIV seropositive and absolute CD4 cell count 13 cells/ microlitre. Mantoux test, HBsAg, HCV Ab, VDRL, scrub typhus, typhoid test were negative. Chest X-ray was also normal. Skin biopsy revealed orthokeratotic epidermis, foamy histiocytes with scattered lymphocytes and plasma cells in dermis, numerous yeast forms of fungus displaying binary fission, morphologically resembling T.marneffei (Figure...
2). On KOH fungal elements were seen, lactophenol cotton blue (LCB) preparation showed metulae bearing brush like conidiophores suggestive of penicillium spp (Figure 3), fungal culture revealed growth of penicillium species after 3 weeks of incubation as a mold with red diffusible pigment (Figure 4). On the basis of clinical, histopathological and mycological findings, a diagnosis of Talaromycosis was established. The patient was treated with oral antifungal, itraconazole 400 mg/day, and he showed improvement in skin lesions after 4 weeks of treatment, however he was lost to follow up thereafter.

On the basis of clinical, histopathological and mycological findings, a diagnosis of Talaromycosis was established. The patient was treated with oral antifungal, itraconazole 400 mg/day, and he showed improvement in skin lesions after 4 weeks of treatment, however he was lost to follow up thereafter.

**Case 2**

A 26 year old male student presented with generalised weakness and asymptomatic skin lesions over face since 1 month. Patient is a k/c/o HIV seropositive and is on 1st line ART (TLE) for past 6 years. On cutaneous examination multiple discrete skin coloured papules, few of them with umbilication and central crusting on face and upper extremities were noted (Figure 5A). Systemic examination was normal.

Laboratory investigations revealed pancytopenia, ESR of 120 mm/ 1st hr, deranged liver enzymes with absolute CD4 count of 46 cells/microlitre. On Skin biopsy, dermis showed numerous yeast form of fungus, both extracellular and intracellular, few of which seen dividing by binary fission, morphologically resembling *T.marneffei*. KOH and fungal culture was diagnostic of penicillium species. Patient was treated with Inj. Amphotericin B 50 mg for 2 weeks followed by tab. Itraconazole 400 mg/ day for 3 months followed by tab. Itraconazole 200 mg/ day till CD4 count >350 cells/microlitre. Patient showed significant improvement in skin lesions after 3 weeks of treatment, and complete resolution in 6 weeks, lost to follow up thereafter.

**Case 3**

A 39 year old male patient presented with fever for past 1 month and itchy skin lesions over face, neck and upper extremities for past 1 week. He is HIV seropositive with pulmonary tuberculosis and is on highly active antiretroviral therapy (HAART) and antitubercular drug (ATD) for past 1 month. On examination multiple discrete skin coloured papules and nodules with umbilication and central crusts on face, neck and bilateral upper extremities were noted. No oro-genital lesions (Figure 5B). Systemic examination was normal.
Laboratory investigations showed Hb 7 gm%, ESR–100 mm/ 1st hr, absolute CD4 cell count of 74 cells/ microlitre, rest of them were within normal limits. Skin biopsy showed similar picture as above two patients, suggestive of penicillium spp. KOH and Fungal culture were diagnostic of penicillium marneffei. Patient was initiated treatment with itraconazole 400 mg/ day, but was lost to follow up thereafter.

The fungus is sensitive to amphotericin B, itraconazole, and ketoconazole. The current recommended treatment regimen is to give amphotericin B 0.6 mg/kg/day for 2 weeks followed by itraconazole 400 mg/day orally in two divided doses for the next 11 weeks. After initial treatment the patient should be given itraconazole 200 mg/day, as secondary prophylaxis for life, if HAART cannot be offered. 11

CONCLUSION

As T. marneffei is an emerging pathogen, a high index of suspicion is required in areas which have geographical proximity to Southeast Asia, North-Eastern India and Bangladesh. Penicilliosis requires further in-depth study with respect to its global distribution, natural history, pathogenesis and the impact of antiretroviral therapy. The mortality rate of untreated penicilliosis is 100%. 12 Any delay in the initiation of antifungal therapy is associated with poor outcome, whereas the therapeutic response is good with early institution of treatment.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Nittayananta W. Penicilliosis marneffei: Another AIDS defining illness in Southeast Asia. Oral Dis. 1999;5:286-93.
2. Ustianowski AP, Sieu TP, Day JN. Penicillium marneffei infection in HIV. Curr Opin Infect Dis. 2008;21:31-6.
3. Vanittanakom N, Cooper CR Jr, Fisher MC, Sirisanthana T. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbio Rev. 2006;19:91-101.
4. Ranjana KH, Priyokumar K, Singh TJ, Gupta ChC, Sharmila L, Singh PN, et al. Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India. J Infect. 2002;45:268-71.
5. Varghese GM, Pise G, Michael SJ, Jacob M, George R. Disseminated Penicillium marneffei infection in a human immunodeficiency virusinfected individual. J Postgrad Med. 2004;50:235-6.
6. Maniar JK, Chitale AR, Miskeen A, Shah K, Maniar A. Penicillium marneffei infection: An AIDS-defining illness. Indian J Dermatol Venereol Leprol. 2005;71: 202-4.

7. Sharma A, Hazarika NK, Barua P, Dey I, Tudu NK. Penicillium marneffei infection in a HIV infected child. Indian J Med Res. 2007;126:580-2.

8. Devi KR, Singh LR, Rajkumari R, Usharani M, Devi KhS, Singh TB. Penicillium marneffei- an indicator disease of AIDS. Indian J Pathol Microbiol. 2007;50:3:674-6.

9. George IA, Sudarsanam TD, Pulimood AB, Mathews MS. An acute abdomen: An unusual presentation of disseminated Penicillium marneffei infection. Indian J Med Microbiol. 2008;26:180-2.

10. Hay RJ, Ashbee HR. Fungal Infections. In: Griffiths C, Barker J, Bleiker T, Chalmers R, Creamer D, editors. Rook’s Textbook of Dermatology. 9th ed. UK: Wiley - Blackwell Publication; 2016: 32.90-1.

11. Supparatpinyo K, Perriens J, Nelson KE, Sirisanthana T. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med. 1998;339:1739-43.

12. Supparatpinyo K, Nelson KE, Merz WG, Breslin BJ, Cooper CR, Kamwan C, et al. Response to antifungal therapy by human immunodeficiency virus infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother. 1993;37(11):2407-11.

Cite this article as: Devi B, Sana S, Meka B, Raj B. Disseminated talaromycosis: an AIDS defining fungal infection. Int J Res Dermatol 2020;6:676-9.